Tapentadol, Urine
Tapentadol is a synthetic opioid agonist that was approved by the FDA in 2008. The mechanism of action is thought to also reflect action as a norepinephrine reuptake inhibitor. Tapentadol is 18 times less potent than morphine but provides analgesia comparable to opioids such as hydrocodone and oxycodone with a more favorable side effect profile. The primary metabolite of Tapentadol is the glucuronide conjugate.
The half-life of tapentadol is approximately 4 hours for the immediate release form and approximately 6 hours in the extended release form.
Approximately 99% of a single oral dose is eliminated in the urine, primarily as glucuronide conjugate. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.
Common side effects: respiratory depression, sedation, nausea, vomiting, dizziness, headache, miosis, constipation, urinary retention, and pruritis. Can be addictive. Overdose effects include apnea, bradycardia, coma, and possible death.
Tapentadol can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.
- Adherence monitoring
- Drug abuse evaluation
- Toxicity/Overdose assessment
Therapeutic Level: 10-100 ng/mL
Toxic level: >200 ng/mL
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.
Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.
Stability
- Ambient: 3-5 days
- Refrigeration: 5-7 days
- Frozen: 30 days
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
- Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
- Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.